[HTML][HTML] Efficacy of NVX-CoV2373 Covid-19 vaccine against the B. 1.351 variant
…, A Pitsi, PL Vollgraaff, A Luabeya… - … England Journal of …, 2021 - Mass Medical Soc
Background The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants threatens progress toward control of the coronavirus disease 2019 (Covid-19) …
variants threatens progress toward control of the coronavirus disease 2019 (Covid-19) …
First-in-human trial of the post-exposure tuberculosis vaccine H56: IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults
AKK Luabeya, BMN Kagina, MD Tameris… - Vaccine, 2015 - Elsevier
Background H56:IC31 is a candidate tuberculosis vaccine comprising a fusion protein of
Ag85B, ESAT-6 and Rv2660c, formulated in IC31 adjuvant. This first-in-human, open label …
Ag85B, ESAT-6 and Rv2660c, formulated in IC31 adjuvant. This first-in-human, open label …
[HTML][HTML] Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial
…, F Kafaar, H Geldenhuys, AKK Luabeya… - The Lancet Infectious …, 2021 - thelancet.com
Background Targeted preventive therapy for individuals at highest risk of incident tuberculosis
might impact the epidemic by interrupting transmission. We tested performance of a …
might impact the epidemic by interrupting transmission. We tested performance of a …
[HTML][HTML] Effectiveness of the Ad26. COV2. S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B …
…, K Ahmed, C Grobbelaar, P Mda, T Dubula, A Luabeya… - The Lancet, 2022 - thelancet.com
Background We aimed to assess the effectiveness of a single dose of the Ad26.COV2.S
vaccine (Johnson & Johnson) in health-care workers in South Africa during two waves of the …
vaccine (Johnson & Johnson) in health-care workers in South Africa during two waves of the …
Safety and immunogenicity of the novel tuberculosis vaccine ID93+ GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo …
…, N Bilek, H Geldenhuys, AKK Luabeya… - The Lancet …, 2018 - thelancet.com
Background A vaccine that prevents pulmonary tuberculosis in adults is needed to halt
transmission in endemic regions. This trial aimed to assess the safety and immunogenicity of …
transmission in endemic regions. This trial aimed to assess the safety and immunogenicity of …
Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial
…, H Geldenhuys, J Shenje, AKK Luabeya… - The lancet Respiratory …, 2019 - thelancet.com
Background Infants are a key target population for new tuberculosis vaccines. We assessed
the safety and immunogenicity of the live-attenuated Mycobacterium tuberculosis vaccine …
the safety and immunogenicity of the live-attenuated Mycobacterium tuberculosis vaccine …
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial
Background Tuberculosis is a major public health problem worldwide. Immunisation with
Mycobacterium bovis BCG vaccine is partially effective in infants, reducing the incidence of …
Mycobacterium bovis BCG vaccine is partially effective in infants, reducing the incidence of …
[HTML][HTML] Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting
…, W Hanekom, A Bollaerts, MA Demoitie, AKK Luabeya… - Vaccine, 2015 - Elsevier
Background Vaccination that prevents tuberculosis (TB) disease, particularly in adolescents,
would have the greatest impact on the global TB epidemic. Safety, reactogenicity and …
would have the greatest impact on the global TB epidemic. Safety, reactogenicity and …
[HTML][HTML] The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
M Tameris, H Geldenhuys, AKK Luabeya, E Smit… - PloS one, 2014 - journals.plos.org
Background Vaccination against tuberculosis (TB) should provide long-term protective
immunity against Mycobacterium tuberculosis (M.tb). The current TB vaccine, Bacille Calmette-…
immunity against Mycobacterium tuberculosis (M.tb). The current TB vaccine, Bacille Calmette-…
[HTML][HTML] Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised …
…, N Lalloo, JJ Lombaard, AL Koen, AK Luabeya… - The Lancet …, 2022 - thelancet.com
Background There is a paucity of data on COVID-19 vaccines in people living with HIV-1,
who could be at increased risk of severe illness and death from COVID-19. We evaluated the …
who could be at increased risk of severe illness and death from COVID-19. We evaluated the …